Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Announces $120 Million Private Placement Financing

Announces Oversubscribed $120 Million Private Placement

Announces $127.5 Million Private Placement Financing

Announces Pricing Of $125 Million Underwritten Offering

Announces Pricing of Upsized Initial Public Offering

Announces Pricing of $240 Million Underwritten Offering of Common Stock

TCG Crossover (“TCGX”) Announces Oversubscribed $1B TCGX Fund II

To be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

Carmot Therapeutics Enters into Definitive Merger Agreement with Roche

Vistagen Announces Pricing of $100 Million Underwritten Offering

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

COMPASS Pathways Announces Up to $285 Million Private Placement Financing

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

Taysha Gene Therapies Announces $150 Million Private Placement Financing

ADARx Pharmaceuticals Announces Oversubscribed $200 Million Series C Financing

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock

Upstream Bio Announces $200M Series B Financing

Alkeus Announces $150 Million Series B Financing

Carmot Therapeutics Raises $150 Million in Series E

Ironwood Enters into Definitive Agreement to Acquire VectivBio

Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

Madrigal Announces Positive Topline Results from the Pivotal Phase 3

Geron Announces Positive Top-Line Results from IMerge Phase 3

Abivax announces successful oversubscribed EUR 130M cross-over financing

Structure Therapeutics Announces Pricing of Upsized Initial Public Offering

VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

Abivax announces successful oversubscribed EUR 49.2M cross-over financing

Upstream Bio Launches with $200M Series A

Plexium Announces $102M Financing

Eikon Therapeutics Announces $517.8 Million Series B Raise

Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing

Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering

ShouTi Secures $100 Million Series B Financing

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

Artios Announces $153 Million Series C Financing

RayzeBio Secures $108 Million Series C Financing

Synthekine Announces $107.5 Million Oversubscribed Series B Financing

Affinia Therapeutics Closes $110 Million Series B Financing

TCG X Raises Inaugural $824 Million Fund to Advance Disruptive Medicines

Entrada Therapeutics Announces Closing of $116 Million Series B Financing

Aktis Oncology Announces $72 Million Series A Financing to Advance Breakthrough Radiopharmaceuticals